Castle BiosciencesCSTL
CSTL
About: Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
Employees: 761
0
Funds holding %
of 7,419 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
272% more call options, than puts
Call options by funds: $3.7M | Put options by funds: $996K
44% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 27
5% more funds holding
Funds holding: 184 [Q3] → 194 (+10) [Q4]
1.41% more ownership
Funds ownership: 92.83% [Q3] → 94.24% (+1.41%) [Q4]
6% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 63
4% less capital invested
Capital invested by funds: $735M [Q3] → $703M (-$31.3M) [Q4]
50% less funds holding in top 10
Funds holding in top 10: 4 [Q3] → 2 (-2) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$37
77%
upside
Avg. target
$37
77%
upside
High target
$37
77%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Baird Catherine Ramsey 28% 1-year accuracy 5 / 18 met price target | 77%upside $37 | Outperform Maintained | 28 Feb 2025 |
Financial journalist opinion
Based on 5 articles about CSTL published over the past 30 days
Neutral
GlobeNewsWire
2 weeks ago
Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships
FRIENDSWOOD, Texas, April 08, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, is supporting key educational programs and initiatives throughout the month of April in recognition of Esophageal Cancer Awareness Month. The Company is proudly collaborating with the Esophageal Cancer Action Network (ECAN), the American Foregut Society (AFS) and The Gut Doctor PodcastLLC to promote esophageal cancer prevention, education and advocacy.
Neutral
GlobeNewsWire
2 weeks ago
Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year
FRIENDSWOOD, Texas, April 07, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received a Top Workplaces USA Award for the fourth consecutive year. The national award program by Energage and USA Today celebrates organizations with 150 or more employees that have built exceptional workplace cultures.
Neutral
GlobeNewsWire
3 weeks ago
Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences' DecisionDx®-Melanoma Test
Consistent with prior studies, published results from Castle's DECIDE study show DecisionDx-Melanoma can both accurately identify patients with less than 5% risk of sentinel lymph node (SLN) positivity, who can safely consider forgoing the sentinel lymph node biopsy (SLNB) surgical procedure, and who are also unlikely to experience disease progression 1,2 As of the last follow-up, all of the patients in the third study analysis with a low-risk DecisionDx-Melanoma test result (Class 1A) were recurrence free, regardless of SLN status 3 FRIENDSWOOD, Texas, April 03, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the recent publication of two papers in the World Journal of Surgical Oncology and Cancer Medicine sharing reports from the prospective, multicenter DECIDE study demonstrating the significant impact of the Company's DecisionDx-Melanoma test on SLNB decision-making for patients with melanoma.3,4 SLNB is a surgical procedure commonly used to determine whether a patient's melanoma has spread to nearby lymph nodes. While useful in the prognosis of patients for whom cancer is found in the lymph nodes, SLNB returns a surgical result that is negative for metastasis in approximately 88% of patients who undergo the procedure.5 Current National Comprehensive Cancer Network® (NCCN) guidelines suggest forgoing SLNB when the likelihood of finding a positive SLN is less than 5%, considering SLNB when the risk is between 5-10% and offering the surgery when the likelihood of positivity is above 10%.
Neutral
GlobeNewsWire
3 weeks ago
Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma
Castle will present data on DecisionDx-Melanoma at the 11th World Congress of Melanoma and 21st European Association of Dermato-Oncology (EADO) Congress.
Neutral
GlobeNewsWire
3 weeks ago
Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups
New, combined validation cohort of 1,412 patients with high-risk squamous cell carcinoma (SCC) demonstrates that the addition of DecisionDx-SCC to Brigham & Women's Hospital (BWH) staging significantly refines metastatic risk prediction in patients classified as High-Risk and Very High-Risk by National Comprehensive Cancer Network (NCCN) guidelines to support improved, risk-aligned treatment pathway decisions Castle will also present new data showing DecisionDx®-Melanoma as a significant predictor of mortality in a real-world cohort of nearly 7,000 patients with early-stage cutaneous melanoma (CM), reinforcing its value in identifying patients who may benefit from treatment plan strategies to improve outcomes FRIENDSWOOD, Texas, March 28, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new data on its risk-stratification tests for patients with skin cancers, DecisionDx-SCC and DecisionDx-Melanoma, via two poster presentations at the NCCN 2025 Annual Conference, being held March 28-30 in Orlando, Florida. As a top five, blue-ribbon abstract at the conference, Castle's poster on DecisionDx-SCC will also be shared in a special oral presentation with the other top-scoring submissions.
Neutral
Business Wire
1 month ago
New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will share new data on its DecisionDx-Melanoma and DecisionDx-SCC tests for patients with skin cancers at the 2025 AAD Annual Meeting.
Neutral
Seeking Alpha
1 month ago
Castle Biosciences, Inc. (CSTL) Q4 2024 Earnings Call Transcript
Castle Biosciences, Inc. (NASDAQ:CSTL ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Camilla Zuckero - VP, IR and Corporate Affairs Derek Maetzold - Founder, President and CEO Frank Stokes - CFO Conference Call Participants Subbu Nambi - Guggenheim Sung Ji Nam - Scotiabank Thomas Flaten - Lake Street Paul Knight - KeyBanc Mason Carrico - Stephens Tom Peterson - Baird Vidyun Bais - BTIG Kyle Mikson - Canaccord Operator Good afternoon, and welcome to Castle Biosciences Fourth Quarter and Full Year 2024 Conference Call. As a reminder, today's call is being recorded.
Positive
Zacks Investment Research
1 month ago
Castle Biosciences, Inc. (CSTL) Surpasses Q4 Earnings and Revenue Estimates
Castle Biosciences, Inc. (CSTL) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to loss of $0.10 per share a year ago.
Neutral
Business Wire
1 month ago
Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #diagnostics--Castle Biosciences, Inc. (Nasdaq: CSTL), today announced its financial results for the fourth quarter and year ended December 31, 2024.
Neutral
Business Wire
1 month ago
Castle Biosciences to Participate in Upcoming Investor Conferences
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences' executive management is scheduled to present a company overview at two investor conferences next month.
Charts implemented using Lightweight Charts™